Meeting
2022 ASCO Annual Meeting
A novel polymeric peptide delivery platform and association with targeted co-delivery of antigens and STING agonists with antitumor immune response.
Authors
Max Mu Wang
Medical Scientist Training Program, Northwestern University, Chicago, IL
Max Mu Wang , Mi Ran Choi , Bin Zhang , Nathan Gianneschi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2564)
DOI
10.1200/JCO.2022.40.16_suppl.2564
Abstract #
2564
Poster Bd #
219
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Effect of cancer vaccine formulation on synergy with anti-CTLA-4 and anti-PD-L1 checkpoint blockade therapy of cancer.
First Author: Yared Hailemichael
Poster
2023 ASCO Annual Meeting
Use of proteomimetic polymers for delivery of tumor antigens and adjuvants through formation of stable electrostatic complexes with small molecule STING agonists.
First Author: Max Mu Wang
Poster
2021 ASCO Annual Meeting
Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.
First Author: Yoshiki Arakawa
Poster
2020 ASCO Virtual Scientific Program
A randomized multicenter phase II trial to evaluate the safety and efficacy of vaccination with folate receptor alpha (FRα) peptides admixed with GM-CSF as an adjuvant versus GM-CSF alone in patients with platinum-sensitive ovarian cancer (EOC).
First Author: Roisin Eilish O'Cearbhaill